EUR/USD likely to find a peak near 1.25: UBS
BURLINGTON, Mass. - Fractyl Health, Inc. (NASDAQ:GUTS), a metabolic therapeutics company with a market capitalization of $82.77 million, has announced the submission of the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, a gene therapy candidate aimed at treating type 2 diabetes (T2D) and obesity. According to InvestingPro data, while the company’s stock has shown strong momentum in recent months, it faces significant financial challenges with an EBITDA of -$95.83 million in the last twelve months. The company plans to initiate first-in-human dosing and report preliminary data in 2026, pending regulatory approval. With analysts setting price targets ranging from $6 to $12, significantly above the current trading price of $1.69, market expectations for this development appear optimistic. For detailed financial analysis and 12 additional expert insights about GUTS, visit InvestingPro.
RJVA-001, part of the Rejuva platform, is designed to deliver a one-time, pancreas-targeted therapy that expresses glucagon-like peptide-1 (GLP-1) in pancreatic beta cells. This approach seeks to enable physiologic hormone secretion while avoiding the high circulating levels associated with side effects of current systemic GLP-1 drug therapies.
The gene therapy is delivered through a minimally invasive endoscopic ultrasound-guided infusion directly into the pancreas. It employs a proprietary version of the human insulin promoter and trafficking signals, allowing nutrient-triggered secretion of GLP-1 from transduced pancreatic beta cells. This method could provide a more physiologic alternative to chronic pharmacotherapy.
Preclinical animal model studies presented at the American Society of Cell and Gene Therapy (ASGCT) 2025 meeting demonstrated the safety, dose-dependent potency, and adaptive nutrient-responsive secretion of RJVA-001 with low circulating GLP-1 levels.
The upcoming Phase 1/2 study aims to evaluate the safety, tolerability, and preliminary efficacy of RJVA-001 in adults with inadequately controlled T2D, despite the use of multiple glucose-lowering agents. The study will include a standardized medication run-in and GLP-1 washout before administering RJVA-001. Participants will be monitored for 12 months for safety, glucose control, immune response, and GLP-1 expression, with a long-term follow-up of up to 5 years.
Fractyl Health is committed to transforming metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies. The company believes that RJVA-001 has the potential to normalize blood glucose and body weight, reducing the burden of lifelong injectable drugs.
This report is based on a press release statement and does not include any speculative or promotional content. The information provided herein is intended to offer a factual overview of Fractyl Health’s ongoing efforts to develop new treatments for metabolic diseases. While the company maintains a healthy current ratio of 2.5, indicating strong short-term liquidity, InvestingPro analysis reveals the company is quickly burning through cash, a critical factor for investors to monitor as clinical trials progress.
In other recent news, Fractyl Health reported its Q1 2025 earnings, highlighting a substantial increase in research and development expenses, which rose to $19.4 million from $14.4 million the previous year. This rise in R&D spending contributed to a widened net loss of $23.7 million, compared to a $3.3 million loss in Q1 2024. Despite these losses, the company maintains strong cash reserves of $42.1 million, ensuring operational stability into late 2025. Fractyl Health is optimistic about its future, with key upcoming catalysts including data releases and regulatory submissions for its Revita and Rejuva platforms.
The company has completed full enrollment of the REMAIN one pivotal cohort, aimed at evaluating Revita for weight maintenance after GLP-1 drug discontinuation. This milestone was achieved ahead of schedule, indicating significant demand and product market fit. Additionally, Fractyl Health is preparing to submit the first CTA module for its Rejuva platform in June, marking a step forward in its regulatory journey. Analysts from firms such as Bank of America Securities and Morgan Stanley are closely monitoring Fractyl Health’s progress, particularly in relation to its innovative solutions in metabolic health. These developments underscore Fractyl Health’s commitment to pioneering scalable outpatient solutions aimed at durable metabolic resets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.